Waverley Pharma Inc.
WAVE.V
TSX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 2.20% | -15.73% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.20% | -15.73% | |||
| Cost of Revenue | -15.97% | -4.20% | |||
| Gross Profit | 34.11% | -30.46% | |||
| SG&A Expenses | 11.01% | -44.15% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.24% | -27.92% | |||
| Operating Income | 154.01% | 81.39% | |||
| Income Before Tax | 19.92% | 46.14% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 19.92% | 46.14% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 19.92% | 46.14% | |||
| EBIT | 154.01% | 81.39% | |||
| EBITDA | 1,758.33% | 101.88% | |||
| EPS Basic | 20.00% | 44.44% | |||
| Normalized Basic EPS | 33.33% | 40.00% | |||
| EPS Diluted | 20.00% | 44.44% | |||
| Normalized Diluted EPS | 33.33% | 40.00% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||